PROCEPT BIOROBOTICS CORP (PRCT)
Health Care · Surgical robotics for urology · NASDAQ
PROCEPT BioRobotics provides an advanced, heat-free robotic surgical solution for the treatment of benign prostatic hyperplasia (BPH) through its proprietary Aquablation therapy.
What PROCEPT BIOROBOTICS CORP does
PROCEPT BioRobotics develops and sells the AquaBeam Robotic System and HYDROS Robotic System, advanced image-guided surgical robotic platforms that deliver proprietary Aquablation therapy—a heat-free waterjet ablation technique—for minimally invasive treatment of benign prostatic hyperplasia (BPH). The company's robotic systems employ single-use disposable handpieces to enable consistent, reproducible surgical outcomes in urology. As of December 31, 2025, PROCEPT had an install base of 912 systems globally, including 718 in the United States.
Themes: surgical robotics, minimally invasive urology, benign prostatic hyperplasia (BPH) treatment, robotic-assisted surgery
Fundamentals
- Price$21.68 as of 2026-08-21 close
- Market cap$1.2B as of 2026-08-21
- 1-year return-44.9% 2025-08-21 close $39.35 → 2026-08-21 close $21.68
- P/En/a negative earnings
- Net margin-32.5% as of 2026-08-24
- Gross margin+64.2% as of 2026-08-24
- ROE-30.6% as of 2026-08-24
- Debt / equity0.15 as of 2026-08-24
- Revenue growth (YoY)+22.7% as of 2026-08-24
- Revenue CAGR (3y)+60.1% SEC XBRL
- Beta0.93 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How PRCT compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How PROCEPT BIOROBOTICS CORP looks technically
PROCEPT BIOROBOTICS CORP (PRCT) is trading 18.5% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 368 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 56, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 9 trading days ago. It is 48.9% below its highest point of the past year. Trading volume is unusually light — only about 49% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 18.5% below its 200-day average, the long-term trend line — a long-term downtrend | -18.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $20.62 | $20.62 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $26.59 | $26.59 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 22.93. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 368 trading days ago — a "death cross", a bearish long-term signal | 368 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend) | 22.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 56, neither overbought (above 70) nor oversold (below 30) | 55.6 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($17.12 to $22.93) — its "stochastic" reading is 78 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 78.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 18 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $42.43 | $42.43 |
|---|---|---|
| From the 52-week high | it is 48.9% below its 52-week high (its highest price of the past year) | -48.9% |
| Above the 52-week low | it is 30.1% above its 52-week low (its lowest price of the past year) | +30.1% |
| Below the 52-week high | it is 48.9% below its highest point of the past year | 48.9% |
| Since a 20-day breakout | it made a new 20-day high about 9 trading days ago | 9 sessions |
| Since a 55-day breakout | it made a new 55-day low about 21 trading days ago | 21 sessions |
| All-time high | its highest closing price on record is $103.81 (set on 2024-11-11) | $103.81 |
| Given back of the 52-week move | over the past year its closes ranged ($16.69 to $41.23), and it has recovered roughly a quarter of its fall from last year’s high — 20% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $31.86 to $32.64. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 20.3% |
| From the all-time high | it is 79.1% below its all-time high | -79.1% |
| Nearest price level | it is trading 5.5% below a resistance level at $22.87 — a price it turned at twice since 2026-04-10, most recently on 2026-08-11. Since 2024-08-21 it has 0 such levels below the current price and 13 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +5.5% |
| All-time low | its lowest closing price on record is $15.38 (set on 2022-01-24) | $15.38 |
| Above the all-time low | it is 41.0% above its all-time low | +41.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 79% of it) | 79th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.29 between its high and its low — about 6.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.29 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $16.84 and $23.45 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $16.84 – $20.14 – $23.45 |
| Typical daily range (% of price) | its price moves about 6.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.0% |
| Stretch from the 200-day average | it is trading 3.8 daily ranges below its 200-day average price (18.5% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 49% of its 30-day average | 0.49× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.2% |
|---|---|---|
| Open gap | it gapped 3.8% above the previous close 9 sessions ago and has not traded back through the level it left behind at 20.41 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.8% |
| Gap filled | a 2.4% gap down opened on 2026-08-06 has been "filled" 11 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 11 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 14.7 percentage points (the stock gained 17.1% while the market gained 2.3%) | +14.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 28.2 percentage points (the stock lost 25.1% while the market gained 3.1%) | -28.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 31.6 percentage points (the stock lost 20.5% while the market gained 11.1%) | -31.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 65.4 percentage points (the stock lost 44.9% while the market gained 20.5%) | -65.4% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 0.6% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 9.2% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -0.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 12% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $24.50 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -11.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% above the average price paid since it last reported on 2026-08-04 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $20.37 — a volume-weighted average of daily closes over 14 sessions, not a true tick-by-tick VWAP. | +6.4% |
Price levels it has turned at before
PRCT last closed at $21.68 on 2026-08-21. Since 2024-08-21 it has turned at 0 prices below its last close and 13 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $22.87 | Resistance | 5.5% above the last close | turned there twice · 2026-04-10 to 2026-08-11 |
| $26.07 | Resistance | 20.3% above the last close | turned there twice · 2026-04-16 to 2026-04-30 |
| $28.57 | Resistance | 31.8% above the last close | turned there twice · 2026-02-25 to 2026-03-17 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $22.93.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $10.74 and $15.39 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $22.93.
This reading has stood for 4 trading days, since 2026-08-18.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · lagging the market · Trading below the Ichimoku cloud · Elliott wave 3 candidates | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.57 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$21.64 range $16.00 – $28.00; median $21.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PRCT
- Consensus EPS estimate-$0.3884 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Unprofitable with negative net margin of -31.82% and significant accumulated deficit; highly dependent on commercialization success and market adoption of Aquablation therapy","Severe stock price decline of -66.22% over one year indicates investor concern about commercial trajectory and competitive positioning","Regulatory and reimbursement risks: continued FDA approvals and insurance coverage required for sustained revenue growth in a competitive surgical robotics market"]
What changed in the latest 10-Q
AI-assisted comparison of PRCT's 10-Q filed 2026-04-30 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Install base increased from 835 to 971 robotic systems globally as of March 31, 2026 (newer filing)
- U.S. install base increased from 653 to 765 systems as of March 31, 2026 (newer filing)
- Revenue of $83.1 million for three months ended March 31, 2026 compared to $69.2 million for three months ended March 31, 2025 (newer filing)
- Net loss of $31.6 million for three months ended March 31, 2026 compared to $24.7 million for three months ended March 31, 2025 (newer filing)
- Cash and cash equivalents of $245.6 million as of March 31, 2026 (newer filing)
- Accumulated deficit of $673.2 million as of March 31, 2026 (newer filing)
- Removed:
- Install base of 835 robotic systems globally as of September 30, 2025 (older filing)
- U.S. install base of 653 systems as of September 30, 2025 (older filing)
- Revenue of $231.7 million for nine months ended September 30, 2025 (older filing)
- Net loss of $65.7 million for nine months ended September 30, 2025 (older filing)
- Cash and cash equivalents of $294.3 million as of September 30, 2025 (older filing)
- Accumulated deficit of $611.7 million as of September 30, 2025 (older filing)
- Reworded:
- Date reference changed from 'As of September 30, 2025' to 'As of March 31, 2026' in Overview section
- Date reference in 'Grow our install base' factor changed from 'As of September 30, 2025' to 'As of March 31, 2026'
- Period comparison changed from 'nine months ended September 30, 2025 compared to nine months ended September 30, 2024' to 'three months ended March 31, 2026 compared to three months ended March 31, 2025'
- Minor punctuation change: 'As urologists gain experience with Aquablation therapy,' changed to 'As urologists gain experience with Aquablation therapy,'
- Notes:
- Older filing text appears truncated at the end ('Outside of the United States, we have ongoing efforts in key markets'), preventing full comparison of the final section
Risk Factors
- Reworded:
- Item 1A Risk Factors page number changed from 29 (filed 2025-11-05) to 27 (filed 2026-04-30)
- Item 2 Unregistered Sales page number changed from 29 (filed 2025-11-05) to 27 (filed 2026-04-30)
- Item 3 Defaults Upon Senior Securities page number changed from 29 (filed 2025-11-05) to 27 (filed 2026-04-30)
- Item 4 Mine Safety Disclosures page number changed from 29 (filed 2025-11-05) to 27 (filed 2026-04-30)
- Item 5 Other Information page number changed from 29 (filed 2025-11-05) to 27 (filed 2026-04-30)
- Item 6 Exhibits page number changed from 30 (filed 2025-11-05) to 28 (filed 2026-04-30)
- Notes:
- The provided text sections contain primarily financial statements and forward-looking statements boilerplate language that is substantially identical between filings. The Risk Factors section itself (Item 1A content) was not provided in either filing, only the table of contents reference. Page number changes reflect document pagination differences, not content changes.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 3 open-market sales by insiders in the last 90 days.
- Last 30 days1 buy ($498315) · 0 sells — 1 buying insider
- Last 90 days1 buy ($498315) · 3 sells ($28479) — 1 buying, 3 selling insiders
- Last 180 days1 buy ($498315) · 3 sells ($28479) — 1 buying, 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-07. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PRCT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding PRCT as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 7,544,703
- Reported value $188,693,015
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
PRCT had 7,091,454 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
PRCT had 12.4% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.12 days to cover at the same settlement.
- Reported short interest (shares) 7,091,454
- Short interest (% of shares outstanding) 12.4%
- Prior settlement (shares) 7,753,703
- Reported change -8.54%
- Days to cover (reported) 5.12
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Intuitive Surgical (ISRG)
- Boston Scientific (BSX)
- Olympus (OCPNY)
- Teleflex (TFX)
- Coloplast (CLPBY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PRCT vs…
Frequently asked questions
What does PROCEPT BIOROBOTICS CORP (PRCT) do?
PROCEPT BioRobotics develops and sells the AquaBeam Robotic System and HYDROS Robotic System, advanced image-guided surgical robotic platforms that deliver proprietary Aquablation therapy—a heat-free waterjet ablation technique—for minimally invasive treatment of benign prostatic hyperplasia (BPH). The company's robotic systems employ single-use disposable handpieces to enable consistent, reproducible surgical outcomes in urology.
What sector is PROCEPT BIOROBOTICS CORP (PRCT) in?
PROCEPT BIOROBOTICS CORP (PRCT) is classified in the Health Care sector. Its industry is Surgical robotics for urology. It trades on NASDAQ.
Who are PROCEPT BIOROBOTICS CORP's (PRCT) competitors?
Notable peers of PROCEPT BIOROBOTICS CORP (PRCT) include Intuitive Surgical, Boston Scientific, Olympus, Teleflex and Coloplast. This peer set is informational only — not financial advice.
Is PROCEPT BIOROBOTICS CORP (PRCT) overbought or oversold right now?
PROCEPT BIOROBOTICS CORP (PRCT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 56, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PRCT come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.